Fig. 6.
Quantitative assessment of the neuroprotective effect of the p38 inhibitor, SB203580. SB203580 was injected into the vitreous at the time of axotomy, injections were repeated 5 and 10 d later, and RGC survival was assessed 14 d after axotomy. At doses of 0.2 nmol (corresponding to a concentration of 1.6 μm in the vitreous) or higher, SB2030580 produced significant prevention of RGC death in the axotomy model (*p < 0.01 by ANOVA with Dunnett's post hoc comparison). Data are expressed as mean cell density ± SD (cells per square millimeter) of hydroxystilbamidine-labeled RGCs (n = 3–6 retinas in each group).